Enhanced antibiotic innovation depends on many things--defining and validating new and better targets, resourcing and facilitating high-quality preclinical and clinical research, streamlining regulation and solving market problems so as to provide incentives to the private sector. Further detail is provided in our recent report (see further information). Acting on these critical steps in concert to provide long-term solutions requires that urgent attention be paid to tackling policy disconnects. Sustaining the political commitment depends on raising the visibility of the problems and their solutions worldwide. The academies of science in the EU recognize their continuing responsibility to help do this.